




REFERENCES

REFERENES

* Abildgaard, U. (1981):

Antithrombin and related inhibitions of coagulation in recent advances in blood coagulation. P.151-173. (Churchill Livingstone, London).

* Abildgaard, U; Fagerhol, U.K., and Egeberg, O. (1970):

Comparison of progressive antithrombin activity and the concentration of three thrombin inhibitors in human plasma. Scan. J. Clin. Invest. 26:349-354.

* Aiach, M.; Frnacois, D.; Proillet, P. et al., (1987):

An abnormal AT III with low heparin affinity: AT III clichy. Br. J. Hematol. 66/4: 515-522.

* Albertazzi, A.; Cappelli, P.; Evangelista, M., Flacco Land Ribaldi, R. (1983):

Influence of hemodialysis treatment on respiratory mechanisms in chronic uremia.

Abstracts of twentieth congress of the European dialysis and transplant association, 22.

* Alkjaersing, N.K.; Fletcher, A.P.; Lewis, M.L., and et al (1976):

Pathophysiological response of the blood coagulation system in acute glomerulonephritis.

Kidney Int. 10:319.

- * Altschuler, G.; Marcus, A.J. and Ullman, H.L. (1960):
Platelets and platelet phosphatides in uremia.
Blood 16:1439-1446.
- * Androssy, K.; Shers, M.; Ritz, E. et al., (1976):
Penicillin-induced coagulation disorder.
Lancet 2:1039-1041.
- * Arruda, J.A.; Carrasquillo, T.; Cubria, A. et al., (1976):
Bicarbonate reabsorption in chronic renal failure.
Kidn. Int. 9:481.
- * Awbery G.J., et al., (1979):
Binding of human thrombin to cultured human endothelial
cells.
J.Biol. Chem. 254:4092.
- * Baillo, R.A. (1981):
New ways in dialysis.
J. Clin. Pathol, 34:1282.
- * Bauer K.A., et al., (1985):
Elevated factor X_a activity in the blood of asymptomatic
patients with congenital antithrombin deficiency.
J. Clin. Invest. 76:826.
- * Beck, N.; Kim, K.S., Wolak, M. and Davis, B.B. (1975):
Inhibition of carboinc anhydrase by parathyroid hormone and
cyclic AMP in rat renal cortex in vivo.
J. Clin. Invest. 55:149.

- * Belit Ser, U.A.; Musialkovaskaia, A.A.; Platonova, T.N.; Ena, I.A.M. (1987):
AT III, functional role and methods of determination (review).
Vopr. Med. Clin. 33 (4):8-15.
- * Bern, M.M. and Green, J. (1982):
Effect of sulfinpyrazone upon antithrombin III and platelet factor 4 in chronic renal failure.
Thrombosis Research 27:457-465.
- * Biggs, R. and Denson, K.W. (1972):
Human blood coagulation, hemostasis and thrombosis, ed. Biggs R, Oxford, Blackwell Scientific Publication.
- * Bilbrey, G.L.; Faloona, G.R.; White, M.G. and Knochel, J.P. (1974):
Hyperglucagonemia of renal failure.
J. Clin. Invest. 53:841.
- * Bilbrey, G.L.; Carter, N.W.; White, M.G.; Schilling, J.F. and Knochel, J.P. (1973):
Potassium deficiency in chronic renal failure.
Kidn. Int. 4:423.
- * Bjork, T, and Nordenman, B. (1976):
Acceleration of the reaction between thrombin and antithrombin III by non-stoichiometric amounts of heparin.
European Journal of Biochemistry. 68:507.

- * Bjork, I. and Lindah, I.U. (1982):
 Mechanism of the anticoagulant action of heparin.
 Mol Cell Biochem. 48:161.
- * Bowers, L.D. and Wang, E.T. (1980):
 Kinetic serum creatinine assays.
 Clin. Chem. 26:555.
- * Boyce, B.F.; Elder, H.Y.; Elliot, H.L., and Fogelman, I. (1982):
 Hypercalcemic osteomalacia due to aluminum toxicity.
 Lancet, Nov, 6:1009.
- * Brandt, P. and Stenbjerg, S. (1979):
 Subcutaneous heparin for thrombosis in pregnant women with
 hereditary antithrombin deficiency.
 Lancet i, 100-101.
- * Brandt, P.; Jespersen, J. and Sorensen, L.H. (1981):
 Antithrombin III and platelets in hemodialysis patients.
 Nephron. 28:1-3.
- * Bricker, N.S. (1969):
 On the meaning of the intact nephron hypothesis.
 Amer. J. MED. 46:1.
- * Buonassisi, V, and Root, M. (1975):
 Enzyme degradation of heparin-related mucopoly-saccharides
 form the surface of the endothelial cell cultures.
 Biochem. Biophys, Acta. 385:1.

* Busch, C., and Owen, W.G., (1982):

Identification in vitro of an endothelial cell surface cofactor for AT III. Parallel studies with isolated perfused rat hearts and microcarrier cultures of bovine endothelium. J. Clin. Invest. 69:726.

* Carlson, T.H.; Atencio, A.C. and Simon, T.L. (1984):

In vivo behavior of radioiodinated rabbit antithrombin III, demonstration of noncirculating vascular compartment. J. Clin. Invest. 74:191.

* Carlson, T.H. Simon, T.L. and Atencio, A.C. (1985):

In vivo behavior of human radioiodinated antithrombin III: distribution among three physiologic pools. Blood. 66:13.

* Carlsson, S.; Hender, U.; Nilsson, I.M., et al., (1970):

Kidney transplantation and fibrinolytic split products in serum and urine. Transplantation 10:366-371.

* Castaldi, P.A.; Rozenberg, M.C. and Stewart, J.H. (1966):

The bleeding disorder of uremia: A quantitative platelet defect. lancet. 2:66-69.

* Chan, T.K. and Chan, V. (1981):

AT III, the major modulator of intravascular coagulation, is synthesized by human endothelial cells. Thromb. Hemost. 46:504.

* Chan, V. and Chan, T.K. (1979):

Demonstration of antithrombin III in fresh and cultured endothelial cells from human umbilical cord.

Thromb. Haemostasis 42,42.

* Cheney, K. and Bonnin, J.A. (1962):

Haemorrhage, platelet dysfunction and other coagulation defects in uremia.

Brit. J. Haemat. 8:215-222.

* Cohen, B.D.; Handelsman, D.G. and Pal, B.N. (1975):

Toxicity arising from the urea cycle.

Kidn. Int. 7:s-285.

* Cohen, B.D.; Stein, I.M. and Bonas, J.E. (1968):

Guanidino succinic aciduria in uremia. A possible alternative for urea synthesis.

Amer. J. Med. 45: 63

* Collen, D., Schetz, J., Holmer E. and Verstraete, M. (1977):

Metabolism of antithrombin III (heparin cofactor) in man: effects of venous thrombosis and heparin administration.

Eur. J. Clin. Invest. 7,27-35.

* Comty, C.M.; Cohen, S.L., and Shapiro, F.L. (1971):

Pericarditis in chronic uremia and its sequelae.

Ann. Intern. Med. 75:173.

* Conard, J. and Samama, M. (1978):

L'antithrombin III.

La Revue de Medicine. 19:2343-2351.

* Czapek, E.E. and Kwaan, H.C. (1979):

The presence of antithrombin activity in platelets.

Thromb. Haemostasis 42:124.

* Dacie, J.V. and Lewis, S.M. (1984):

Basic haematological techniques. In Practical Haematology

6th ed P.43-41 (ed) Churchill Livingstone.

* Damus, P.S., Hicks, M, and Rosenberg, R.D. (1973):

Anticoagulant action of heparin.

Nature. 246: 355-357.

* Davis, D.W. (1971):

The measurement of AT III (serum antithrombin) level as a possible diagnostic aid.

Med. J. Austr. 1:959-962.

* Davies, D.P.; Hughes, A.; Lumar, G.D. and Tonks, R. (1968):

Hypermagnesaemia and platelet function in uraemic bleeding.

Lancet, 1:301.

* Davis, M., Muckle, T. and Cassel-Smith, A. (1972):

Platelet function in uraemia.

Brit. J. Urology, 44:387-394.

* De Stefano, V.; Leone, G.; Ferrelli, R. et al., (1987):

Further characterization of a pathological isoantithrombin with no affinity for heparin. (AT III Roma).

Thromb. Res. 48/1:23-30.

* Deykin, D. (1983):

Uraemic bleeding. Kidney Int. 24:698-705.

- * Docci, D.; Bilancioni, R.; Turci, F. and Baldrati, L. (1986):
What plasma antithrombin III after haemodialysis?
Nephron 42:267.
- * Drukker, E.W. (1978):
Replacement of renal failure by dialysis. Dialysis review,
edited by Davison, A.M., pitman Medical 11.
- * Drueke, T. (1979):
Gastrointestinal disorders in chronic renal failure.
Nephrology, Hamburger J, Crosnier J, and Grunfeld JP, John
wiley and sons Inc. New York, London, Sidney, Toronto. 331.
- * Drueke, T. and Jungers, P. (1979):
Cardiovascular complication in chronic hemodialysis.
Nephrology, Hamburger J, Crosnier J, and Grunfeld JP, John
Wiley and sons Inc. New York, London, Sidney, Toronto. 1231.
- * Editorial: Familial AT III deficiency (1983):
Lancet, i:1021.
- * Eknoyan, G.; Wacksmo, S.J. Glueck, H. and Will, J.J. (1969):
Platelet function in renal failure.
N.Engl. J. Med., 280:677.
- * Ellis, V.; Scully, M.; Mac Gregor, I. and Kakkar, V. (1982):
Inhibition of human factor X_a by various plasma protease in-
hibitors.
Biochem. Biophys. Acta. 701:24.
- * Fagergol, M.K.; Akilgaard, U. and Kornstad, L. (1971):
Antithrombin III concentration and ABO blood groups.
Lancet. 2:664-665.

* Feldman, H.A. and Singer, I. (1975):

Endocrinology and metabolism in uremia and dialysis, a clinical review. Medicine. 54:345.

* Fernandez, F.; Goudable, C., and Sie, P. (1985):

Low hematocrit and prolonged bleeding time in uremia. Effect of red cell transfusion.

Br. J.Haematol. 59:139-148.

* Finazzi, G. et al., (1985):

Purification of antithrombin (Vicenza) a molecule with normal heparin affinity and impaired reactivity to thrombin.

Br. J.Haematol. 59:259.

* Finkelstein, P.O. and Hayslett, J.P. (1974):

Role of medullary structures in functional adaptation of renal insufficiency.

Kidn. Int. 6:419.

* Fontcuberta, J.; Grau, E.; Rubio, M. et al., (1988):

Quantitative and qualitative congenital deficiency of AT III a new molecular variant cells AT III-Barcelona 2.

Thromb. Res. 51/1:75-81.

* Gafter, U.; Bessler, H.; Malachi, T. et al., (1987):

Platelet count and thrombopoietic activity in patients with chronic renal failure.

Nephron 45:207-210.

*** Gallus, A.S. et al., (1984):**

Oral contraceptives and surgery; reduced antithrombin and antifactor X_a levels without postoperative venous thrombosis in low-risk patients. *Thromb. Res.* 35:513.

*** Gilabert, J.; Fernandez, J.A.; Espana, F.; Aznar, J. and Estelles, A. (1988):**

Physiological coagulation inhibitors (protein S, protein C and AT III) in severe pre-eclamptic states and in users of oral contraceptives.

Thromb, Res. 49 (3) 319-29.

*** Girolami, A. et al., (1984):**

AT III Trento: a new congenital AT III abnormality with a peculiar crossed immunoelectrophoretic pattern in the absence of heparin.

Acta. Haematol. 72:73.

*** Gitel, S.N. and Wessler, S. (1975):**

Plasma AT III: a quantitative assay of biological activity. *Thromb. Res.* 7:5.

*** Griffith, M.J. (1979):**

Kinetic analysis of heparin-enhanced antithrombin III/thrombin reaction: reaction rate enhancement by heparin thrombin association.

J. Biol. Chem. 254:12044.

*** Grunfeld, J.P. (1979):**

Chronic renal failure, Nephrology, Hamburger J, Crosnier J, and Grunfeld JP, John Wiley and sons Inc. New York, London, Sidney, Toronto. 283.

*** Gura, V.; Creter, D. and Levi, J. (1982):**

Elevated thrombocyte calcium in uraemia and its correction by 1,25 (HO)₂ vitamine D treatment.
Nephron, 30:237-239.

*** Hall, C.L. (1978):**

Fibrinolysis in renal diseases. Current fundamental and clinical concepts (ed by P.J. Gaffney and S. Balkuvlutin)
Academic Press, London P. 207.

*** Hamberg, M.; Svensson, J and Samuelsson, B. (1982):**

Thromboxanes, a new group of biologically active compounds derived from prostaglandin endoperoxides.
Proc. Nat. Acad. Sci. USA. 72:2994-2997.

*** Harrington, A.R. and Zimmerman, S.W. (1982):**

Chronic renal failure. Renal pathophysiology, John Wiley and sons Inc. New York, Chichester, Brisbane, toronto, 185.

*** Hedner, U. and Nilson, I.M. (1971):** ✓

Urokinase inhibitors in serum in a clinical series.
Acta Med. Scand. 189:185-189.

*** Hedner, U. and Nilsson, I.M. (1972):**

Antithrombin III in clinical material. 7th European conference microcirculation.
Aberdeen, Part II, Bibl Anat. 12:267-271.

* High, K.A. (1988):

AT III, protein C, and S proteins. Naturally occurring anticoagulants proteins.

Arch. Path. Lab. Med. JAn Vol: 112 (1):28-36.

* Holdrirt, A.; Ewals, M.; Reichert, W. and Haanene, C. (1969):

Mathematical correlation between ADP-induced aggregation and subsequent disaggregation.

Scand. J. Haemat. 6:354.

* Holmer, E.; Soderstrem, G. and Andersson, L.O. (1979):

Studies on the mechanism of the rate enhancing effect of heparin on the thrombin-antithrombin III reaction.

European Journal of Biochemistry. 93:1-5.

* Holmes, E.W.; Kelley, M.N. and Wyngaarden, J.B. (1972):

The kidney and uric acid excretion in man.

Kidn. Int. 2:115.

* Horowitz, H.I. (1970):

Uremic toxins and platelet function.

Arch. Intern. Med. 7:823.

* Horowitz, H.; Cohen, B.; Martines, P. and Papayocanou, N.F.

(1967):

Deffective ADP-induced platelet factor 3 activation in uraemia,

Blood 30 (3): 331-334.

* Hutton, R.A. and O'shea, M.J. (1968):

Haemostatic mechanism in uraemia.

J. Clin. Path. 21:406-411.

* Isacson, S. and Nilsson, I.M. (1969):

The kidney and fibrinolytic activity in the blood.

Thromb. Diath. Haemorrh. 22: 211-215.

* Jespersen, J. et al., (1985):

Protection against venous thrombosis in an AT III deficient patient suffering from episode of arterial thrombosis requiring major surgery. Effects of oral stanazol in combination with subcutaneous heparin and intravenous AT III.

Am. J. Clin. Pathol. 83:768.

* Johnson, W.J., Hagge, W.W.; Wagoner, R.D. et al., (1975):

Toxicity arising from urea.

Kid. Intern. 7:81-100.

* Joist, J.H.; Pechan, J.; Schikowski, U. et al., (1959):

Untersuchungen zur nature and atologie der uramischen.

Thrombe. Verh. Dtsch. Ges. Inn. Med. 75:476.

* Jones, J.D. and Burnett, P.C. (1975):

Creatinine metabolism and toxicity.

Kidn. Int. 7:S-294.

* Jorgensen, K.A. and Stoffersen, E. (1977):

Heparin-induced antithrombin III deficiency.

Lancet 2,1231.

* Jorgensen, K.A. and Stoffersen, E. (1979):

Antithrombin III in uremia.

Scand. J. Urol. Nephrol. 13:299-333.

- * Jorgensen, M.; Eriksen, H.O. and Tranobjarg, L. (1985):
 Plasma antithrombin III concentration in patients on regular
 haemodialysis treatment.
 Nephron 40:22-24.
- * Jorgensen, M.; Petersen, L.C. and Thorsen, S. (1984):
 Purification and characterization of hereditary abnormal
 antithrombin III with impaired thrombin binding.
 J. Lab. Clin. Med. 104:245-256.
- * Jungers, P. (1979):
 Nitrogenous retention in chronic renal failure.
 Nephrology, Hamburger J, Crosnier J, and Grunfeld JP, John
 Wiley and sons Inc. New York, London, Sidney, Toronto. 299.
- * Jungers, P. and Man, M.K. (1979):
 Neurological manifestations of chronic renal failure.
 Nephrology, Hamburger J, Crosnier J, and Grunfeld JP, John
 Wiley and sons Inc. New York, London, Sidney, Toronto. 335.
- * Jungers, P.; Man, M.K. and Brentano, J.F. (1979):
 Chronic hemodialysis-other methods.
 Nephrology, Hamburger J, Crosnier J, and Grunfeld JP, John
 Wiely and sons Inc. New York, London, Sidney, Toronto. 1267.
- * Kaegi, A.; Pineo, G.F.; Shimizu, A. et al., (1974):
 Arteriovenous shunt thrombosis-prevention by sulfinpyrazone.
 N. Engl. J. Med. 290:304-306.
- * Kakkar, V.V.; Bentley, P.G.; Scully, M.F. et al., (1980):
 Antithrombin and heparin.
 Lancet 1,103.

- * Kant, K.S.; Pollak, V.E.; Cathey, M.; Goetz, D. and Berlin, R.
(1981):
Multiple use of dialyzers: safety and efficacy.
Kidn. Int., 19:728.
- * Kasper, C.K. (1975):
Thromboembolic complications.
Thromb. Haemost. 33:640.
- * Kauffmann, R.H.; Veltkamp, J.J.; Van Tilbrug, H.H. and Van,
E.S. (1978):
Acquired AT III deficiency and thrombosis in the nephrotic
syndrome.
Amer. J. MED. 65:607-13.
- * Kierkegaard, A. (1985):
Side and site of deep vein thrombosis in women using oral
contraceptives.
Acta.Obstet. Gynecol. Scand. 64:399.
- * Kim, Y.S.; Lee, K.B. and Linhardt, R.J. (1988):
Microheterogeneity of plasma glycoprotein heparin cofactor
II and antithrombin III and their carbohydrate analysis.
Thromb. Res. 51 (1):97-104.
- * Kim, Y.S.; Lee, K.B. and Linhardt, R.J. (1988):
Division of medicinal and natural products chemistry, col-
lege of pharmacology, University of Iowa, Iowa City IA.
Thromb. Res. 51:97-104.

* Knochel, J.P. and Seldin, D.W. (1981):

The pathophysiology of uremia. The kidney, Brenner and Rector, Second edition, W.B. Saunders company.
Philadelphia, London, Toronto, 2137.

* Knot, E.A.R.; Dejong, E.; Tencate, J.W. et al., (1986):

Purified radiolabeled antithrombin III metabolism in three families with hereditary AT III deficiency: application of a three compartment model.
Blood 87:93-8.

* Knudsen, F. and Dyerberg, J. (1985):

Platelet and antithrombin III in uremia: The acute effect of haemodialysis.
Scand. J. Clin. Lab. Invest. 45:341-347.

* Knudsen, F. and Nielsen, A.H. (1986):

Antithrombin III is not an indicator of dialyzer biocompatibility.
Nephron 42:270.

* Knudsen, F.; Nielsen, A.H. and Kristensen, D.S. (1985):

The effect of dialyser membrane material on intradialytic changes in platelet count, platelet aggregation, circulating platelet aggregates and antithrombin III.
Scand J.Urol. Nephrol. 19:227-232.

* Koid, T.; Odani, S.; Takahashi, K, et al., (1984):

AT III Toyama: replacement of arginine-47 by cysteine in hereditary abnormal AT III that lack heparin-binding ability
Proc, Natl. Acad, Sci. USA, 81:289.

* Kokko, J. (1982):

Chronic renal failure. Cecil Textbook of Medicine, sixteenth edition, Wyngaarden JB, and Smith LH, W.B. Saunders company. Philadelphia, London, Toronto, 501.

* Kolb, W.P., and Kolb, L.M. (1983):

Antithrombin III binding to SC 5 b-9 attack complexes of human complement: dissociation of a modified AT III derivative subsequent to complex formation.

Biochemistry. 22:496.

* Kopple, J.D. (1978):

Abnormal amino acid and protein metabolism in uremia.

Kidney Inter. 14:340-348.

* Kopple, J.D. and Swendseid, M.E. (1975):

Protein and amino acid metabolism in uremic patients undergoing maintenance hemodialysis.

Kidn. Int. 7:S-64.

* Kraut, J.; Gafter, U.; Brautbar, N.; Miller, J. and Shinaborger, J. (1981):

Prevention of hypoxemia during dialysis by the use of sequential isolated ultrafiltration-diffusion dialysis with bicarbonate dialyzate.

Clin. Neph. 15 (A); 181.

* Kuhlback, B. (1957):

The bleeding tendency in chronic renal failure.

Acte Medica scandinavia, 157:173-177.

- * Kurachi, K.; Fujikawa, K.; Schner, G. et al., (1976):
Inhibition of factor IX_a and X_a by antithrombin III.
Biochemistry. 15:373-377.
- * Lane, D.A.; Lowe, G.D.; Flynn, A. et al., (1987):
AT III Glasgow: a variant with increase heparin affinity and
reduced ability to inactivate thrombin, associated with
familial thrombosis.
Br. J. Hematol. 66/4:523-527.
- * Larsson, S.O. (1971):
On coagulation and fibrinolysis in renal failure.
Scand. J. Haematol. supp . 15.
- * Lascelles, P.T. and Taylor, W.H. (1966):
The effect upon tissue respiration in vitro of metabolites
which accumulate in uremic coma.
Clin. Sci. 31:403.
- * Leaf, A. (1956):
On the mechanism of fluid exchange of tissues in vitro.
Biochem. J. 62:241.
- * Leone, G, et al., (1984):
Different forms of AT III congenital defect: a study by
crossed immunoelectrofocussing.
Scan. J. Hematol. 33:410.
- * Lewis, J.H., Zucher, M.B. and Farguson, J.H. (1976):
Bleeding tendency in uraemia.
Blood. 12:1073.

* Lindner, A.; Charra, B.; Sherrard, D.J. and Scribner, B.H.

(1974):

Accelerated atherosclerosis in prolonged maintenance hemodialysis.

N. Engl. J. Med. 290:697.

* Lindsay, R.M.; Bolton, C.F.; Clark, W.F. and Linton, A.L.

(1983):

The effect of alterations of uremic retention products upon platelet and peripheral nerve function.

Clin. Neph. 19 (3): 110-115.

* Lindsay, R.M.; Prentice, C.R.M.; Davidson, J.F. et al., (1972):

Haemostatic changes during hemodialysis associated with thrombus formation on dialysis membranes.

Br. Med. J. 454-458.

* Liveson, J.A.; Gardner, J. and Bornstein, M.B. (1977):

Tissue culture studies of possible uremic neurotoxins: Myoinositol.

Kidn, Int. 12:31.

* Livo, M.; Gotti, E.; Marchesi, D. et al., (1982):

Uremic bleeding: Role of anaemia and beneficial effect of red cell transfusion. Lancet 2:1013-1015.

* Lollar, P. and Owen, W.G. (1980):

Clearance of thrombin from circulation in rabbits by high-affinity binding sites on endothelium. Possible role in the inactivation of thrombin by antithrombin III.

J. Clin. Invest. 66:1222.

- * Man, N.K. and Jungers, P. (1979):

Chronic hemodialysis-Basic principles, and equipment.

Nephrology, Edited by Hamburger J, Crosnier J, and Grunfeld JP, John Wiley and sons Inc. New York, London, Sidney, Toronto. 1199.

- * Mansell, M.A.; Nunan, T.O.; Laker, M.F.; Boon, N.A. and Wing, A.J. (1979):

Incidence and significance of rising blood acetate levels during hemodialysis.

Clin. Nephrol. 12 (1):22.

- * Mansini, G.; Carbonara, A.O. and Heremans, J.F. (1965):

Immunochemical quantitation of antigens by single radial immunodiffusion.

Int. J. Immunochem. 2:235-254.

- * Marciniak, E. and Gockerman, J.P. (1977):

Heparin induced decrease in circulating AT III.

Lancet. 2:581-84.

- * Marciniak, E. and Romand, E.H. (1987):

Catabolism and distribution of functionally heterogenous human antithrombin III.

J. Lab. Clin. Med. 109:89-96.

- * Marcum, J.A. and Rosenberg, R.D. (1984):

Anticoagulantly active heparin-like molecules from vascular tissue.

Biochemistry. 33:1730.

- * Marcus, A.J.; Zuker-Franklin, D.; Safier, L.B. et al., (1966):
Studies on human platelet granules and membranes.
J. Clin. Invest. 45:14.
- * Massry, S.G. and Goldstein, D.A. (1979):
The search for uremic toxins.
Clin. Nephrol. 11:181-189.
- * Matthews, C.M.B. (1957):
The theory of tracer experiments with I^{131} labeled plasma
proteins.
Phys. Med. Biol. 2:36-53.
- * McGann, M.A. and Triplett, D.A. (1982):
Interpretation of antithrombin III activity.
Lab. Med. 13,12:742-749.
- * Michiels, J.J. et al., (1984):
Prophylaxis of thrombosis in AT III deficiency women during
pregnancy and delivery.
Eur. J. Obstet. Gynecol. Repord, Biol. 18:149.
- * Michalis, J.J. and Van Vleit, H.H. (1984):
Hereditary antithrombin III deficiency and venous throm-
bosis.
Neth. J. Med. 27:226.
- * Mitch, W.E. and Walser, M. (1977):
Effects of oral neomycin and kanamycin in chronic uremic
patients on nitrogen balance.
Kidn. Int. 11:123.

- * Moia, M.; Vizzitto, L.; Gattaneo, M. and Mannucei, P. (1987):
Improvement in the hematocrit defect in uraemia after treatment with recombination human erythropoietin.
Lancet, 28:1227-29.
- * Moxley, M.A.; Bell, H.H.; Wagel, S.R.; Allen, D. and Ashmore, J. (1974):
Parathyroid hormone stimulation of glucose and urea production in isolated liver cells.
Amer. J. Physiol. 227:1058.
- * Odegaard, O.R.; Fagerhol, M.K. and Lie, M. (1976):
Heparin cofactor activity and antithrombin III concentration in plasma related to age and sex.
Scan. J. Hemat. 17:258-262.
- * Osta, G.M. et al., (1981):
Multiple functional domains of heparin molecules.
Proc. Natl. Acad. Sci. USA. 78:829.
- * Panicucci; Sagripanti, A.; Pinori, E.; Vispi, M. et al., (1983):
Comprehensive study of hemostasis in chronic uremia.
Nephron 33:5.
- * Parsons, F.M. (1983):
History of dialysis, Part I hemodialysis 1861-1914.
Outlook, January, 23. Part II hemodialysis 1914-1950.
Outlook. April, 19.
- * Patton, C.J. and Crouch, S.R. (1977):
Determination of serum urea.
Anal. Chem. 49:464.

* Perides, A.M.; Alvarez-Ude, F. and Kerr, D.N. (1975):

Clofibrate induced muscle damage in patients with chronic renal failure.

Lancet. 2:1279.

* Peterson, C.B. et al., (1985):

Isolation and characterization of AT III variant with reduced carbohydrate content and enhanced heparin binding.

J. Biol. Chem. 260:610.

* Peterson, C.; Kelly, R.; Minard, B. Gawley, L.P. (1978):

Antithrombin III: comparison of functional and immunological assays. Am. J. Clin. Pathol. 69:500.

* Peterson, T.E.; Dudek-Wajciechowska, G.; Sottrup-Jensen, J. and Magnusson, S. (1979):

Primary structure of antithrombin III (heparin-cofactor): partial homology between α 1-antitrypsin and antithrombin III. In collen D, Wiman B, Verstraete M (eds): the physiological inhibitors of blood coagulation and fibrinolysis P. 43. Amsterdam, Elsevier/North Holland.

* Pitney, W.R.; Potter, M.; McIver, M. and Jeremy, D. (1967):

Haemostasis in renal disease.

Med. J. of Australia. July 1:4-6.

* Podack, E.R.; Curd, J.G.; Griffin, J.M. and Muller-Eberhard, H.J. (1978):

Dual function of the S-protein in the complement and coagulation systems of human plasma.

Clin. Res. 26:507 A.

- * Popovich, R.P.; Moncrief, J.W. and Molph, K.D. (1978):
Continuous ambulatory peritoneal dialysis.
Ann. Intern. Med. 88:449.
- * Proctor, R.R. and Rapaport, S.I. (1961):
The partial thromboplastin time with koalin: A simple
screening test for first stage plasma clotting factor
dificiencies.
Am. J. Clin. Path. 36:212-219.
- * Prosser, D. and Parsons, B. (1975):
The case for a specific uremic myocardiopathy.
Nephron, 15:4.
- * Rabiner, S.F. (1972):
Bleeding in uremia.
Med. Clin. North. Am. 56:221-233.
- * Rabiner, S.F. and Hrodeck, O. (1968):
Platelet factor 3 in normal subjects and patients with renal
failure.
J. Clin. Invest. 47:901-912.
- * Rabiner, S.F. and Molinas, F. (1970):
The role of phenol and phenolic acid on the thrombocytopathy
and defective platelet aggregation of patients with renal
failure. Am. J. Med. 49:346-351.
- * Rath, C.E.; Mailliard, J.A. and Schreiner, G.E. (1957):
Bleeding tendency in araemia.
New Engl. J. Med. 257:808-811.

- * Reaven, G.M.; Weisinger, J.R. and Swenson, R.S. (1974):
 Insulin and glucose metabolism in renal insufficiency.
 Kidn. Int. 6:S-63.
- * Remuzzi, G. (1988):
 Bleeding in renal failure.
 Lancet, 28:1205-1207.
- * Remuzzi, G.; Cavenaghi, A.E.; Mecca, G. et al., (1977):
 Prostacyclin-like activity and bleeding in renal failure.
 Lancet 2:1195-1197.
- * Remuzzi, G.; Livio, M.; Cavenaghi, A.E., et al., (1978):
 Unbalanced prostaglandin synthesis and plasma factors in
 uremic bleeding.
 A hypothesis. Thromb. Res. 13:531-536.
- * Remuzzi, G.; Marchesi, D.; Cavenaghi, A.E.; et al., (1979):
 Bleeding in renal failure: A possible role of vascular pros-
 tacyclin (PGI₂).
 Clin. Nephrol. 12:127-131.
- * Remuzzi, G.; Benigni, A.; Dosesini, P. and Donati, M.B. (1982):
 Platelet function in patients on maintenance hemodialysis:
 depressed or enhanced?
 Clin. Neph. 17 (2):60-63.
- * Reven, O.; Fagerhol, M.K. and Abildgaard, U. (1973): ✓
 Changes in antithrombin III levels following cessation of
 anticoagulant therapy.
 Acta. Med. Scand. 193, 307.

- * Rodgers, G.M. and Shuman, M.A. (1986):
Congenital thrombotic disorders.
Am. J.Hematol. 21:419.
- * Rosenberg, R.D. (1975):
Action and interactions of antithrombin and heparin.
N. Engl. J. Med. 16:146-151.
- * Rosenberg, R.D. (1977):
Chemistry of the hemostatic mechanism and its relationship
to the action of heparin.
Fed. Proc. 36:10.
- * Rosenberg, R.D. (1979):
Mechanism of antithrombin action and the structural basis of
heparin's anticoagulant function. In Bing DH (eds):
the chemistry and physiology of the human plasma proteins.
P. 353. New York, Pergamen press.
- * Rosenberg, R.D. and Danus, P.S. (1973):
The purification and mechanism of action of human
antithrombin-heparin cofactor.
J. Biol. Chem. 248:6490.
- * Rosenberg, B.D. and Rosenberg, J.S. (1984):
Natural anticoagulant mechanisms.
J. Clin. Invest. 74:1-6.
- * Salzman, E.W. and Neri, L.L. (1966):
Adhesiveness of blood platelets in Uraemia.
Thromb. Diath. Haemorrh. 15:84.

- * Sas, G. Peto, L., Banhegyi, B.G. and et al., (1980):
Heterogeniciety of the classical AT III deficiency.
Thrombo. Haemost. 43:133.
- * Sas, G.; Blasko, G.; Banhegyi, D.; Jako, J. and Palos, L.A.
(1974):
Abnormal AT III (antithrombin III Budapest) as a cause of
familial thrombophilia.
Thrombosis et Diathesis Hemorrhagica. 32:105-115.
- * Shapiro, M.E. et al., (1981):
Acute aortic thrombosis in AT III deficiency.
J.A.M.A. 245:1759.
- * Shapiro, S.S. and Anderson, D.B. (1977):
Thrombin inhibition in normal plasma. In Lundblad RL, Fenton
JW, Mann KG (eds):
Chemistry and Biology of Thrombin. P. 361.
Ann Arbor Science Publishing.
- * Shattil, S.J. (1984):
Diagnosis and treatment of recurrent venous thrombosis.
Med. Clin. North. Am . 68:577.
- * Shaw, A.B. and Scholes, M.C. (1967):
Reticulocytosis in renal failure.
Lancet. 2:799.

- * Simionescu, M.; Simionescu, M.; Silbert, J.E. and Palade, G.E.
(1981):
Differentiated microdomains on the luminal surface of the
capillary endothelium II. Partial characterization of their
anionic sites.
J. Cell. Biol. 90:614.
- * Simpsopn, D.P. (1971):
Control of hydrogen ion homeostasis and renal acidosis.
Medicine. 50, 503.
- * Slavin, R.G. and Fitch, C.D. (1971):
Inhibition of lymphocyte transformation of guanidino suc-
cinic acid a surplus metabolites in uremia.
Experiential. 27:1340.
- * Sorensen, P.J. et al., (1980):
Familial junctional antithrombin III deficiency.
Scand. J. Hematol. 24:105.
- * Soszka, J.; Rydzewski, A and Mysliwiec, M. (1983):
Normal response of uremic platelets to thromboxane A₂ an-
tagonists.
Nephron 35:267-268.
- * Stead, M.W.; Kaplan, A.P. and Rosenberg, R.D. (1976):
The inhibitor of human activated Hageman factor (H.F.) by
human antithrombin heparin cofactor (AT).
Journal of Biological chemistry. 251:6481-6488.

- * Steif, T.W. and Heimburger, M. (1988):
 Oxidative inactivation of purified human alpha-2 antithrombin, AT III and C₁-inhibitor.
 Thromb. Res. 4916:581-89.
- * Stephens, A.W.; Thalley, B.S. and Hirs, C.H. (1987):
 AT III Denver, a reactive site variant.
 USA. J.Biol. Chem. 262/3:1044-1048.
- * Stewart, J.H. (1967):
 Platelet number and life span in acute and chronic renal failure.
 Thromb. Diath. Haemorrh., 17:532-542.
- * Stone, A.L.; Beeler, D.; Costa, G. and Rosenberg, R.D. (1982):
 Circular dichroism spectroscopy of heparin-antithrombin interactions.
 Proc. Natl. Acad. Sci. USA. 79:7190.
- * Suzuki, K.; Wishioka, J. and Hashanots, S. (1983):
 Protein C inhibitor purification from human plasma and characterization.
 J. Biol. Chem. 258:163-168.
- * Szwed, J.; Handt, A.; Farber, M.O. and Kesler, P. (1982):
 The effect of hemodialysis on oxygen transport in chronic uremics.
 Am. J. Med. Sci. 283 (2):50.

- * Tatra, G.; Gruber, W. and Breite-Necker, G. (1974):
Quantitative immunologische Bestimmung der antithrombin
III-konzentration bei normaler.
Gynakologie. 217:127-130.
- * Teger-Nilsson, A.C. (1975):
Antithrombin in infancy and childhood.
Acta. Paediat. Scand 64:624-628.
- * Thaler, E. and Lechner, K. (1981):
Antithrombin III deficiency and thromboembolism.
Clin. Hematol. 10:369.
- * Tison, P.; Gernacek; Silvanova, E. and Dzurik, R. (1981):
Uremic toxins and blood platelet carbohydrate metabolism.
Nephron 28:192-195.
- * Tran, T.H. et al., (1980):
Purification and partial characterization of hereditary ab-
normal AT III fraction of a patient with recurrent thrombop-
hlebitis.
Thromb. Haemost. 44:87.
- * Turney, J.H.; Fewell, M.; Williams, L.C.; Dodd, N. and Weston,
M.J. (1982):
Paradoxical behavior of antithrombin III during hemodialysis
and its prevention with prostacyclin.
Clinical Nephrology. 17:31-5.
- * Van Ypersele de Strihou C, (1977):
Potassium homeostasis in renal failure.
Kidn. Int. 11: 491.

- * Vassalli, P. and McCluskey, R.T. (1965):
The coagulation process and glomerular disease.
Am. J. Med. 39:179-183.
- * Vaziri, M.D.; Toohey, J.; Paule, P.; Alikhani and Hung, E.
(1984):
Coagulation abnormalities in patients with end-stage renal
disease treated with hemodialysis.
Int. J. Artif. Org. 7, 6:323-326.
- * Vaziri, M.D.; Winer, R.L.; Alikhani, S. et al., (1985):
Antithrombin deficiency in end stage renal disease as-
sociated with paraplegia, effect of hemodialysis.
Arch. Phys. Med. Rehab. 66:307-309.
- * Vlachoyannis, J. and Schoeppe, W. (1982):
Adenylate cyclase activity and cAMP content of human
platelets in uraemia.
Eur. J. Clin. Invest. 12:379-381.
- * Von Kaula, E. and Von, Kaula, R.N. (1967):
Antithrombin III and diseases.
Am. J. Clin. Pathol. 48:69-80.
- * Wardle, E.N. and Taylor, G. (1968):
Fibrin breakdown products and fibrinolysis in renal disease.
J. Clin. Path. 21:141-146.
- * Warrell, R.P., Hultin, M.B. and Collier, B.S. (1979):
Increased factor VIII, Von willebrand factor antigen and von
willebrand factor activity in renal failure.
Am. J. Med. 66:220-228.

*** Welbourne, T.C. (1973):**

Influence of chronic acidosis on plasma glutamine and urea production in the nephrectomized rat.

Amer. J. Physiol. 224:796.

*** Wing, A.J. (1968):**

Optimum calcium concentration of dialysis fluid for maintenance hemodialysis.

Brit. Med. J. 4:145.

*** Willoughby, M.L. and Crouch, S.J. (1961):**

An investigation of the haemorrhagic tendency in renal failure.

Brit. J. Haemat. 7:315-326.

*** Winter, J.H. et al., (1984):**

Prophylactic therapy with stanazolol in patients with familial AT III deficiency.

Br. J. Haematol. 57:527.

*** Wintrobe, M.M.; Lee, G.R.; Baoggs, D.R. et al., (1981):**

"Mature erythrocyte and platelet". In: Clinical Haematology, 8th ed. (Lea and Febiger, Philadelphia, P. 405-417).

*** Wolf, M. et al., (1982):**

A new familial variant of AT III: AT III paris.

Br. J. Haematol. 51:285.

*** Wolf, M.; Boyer-Neumann, C.; Meyer, et al., (1987):**

Purification and further characterization of AT III Milano:

Lack of reactivity with thrombin.

Thromb. Hemostasis. 58/3:888-892.

- * Woo, K.T.; Wei, S.S.; Lee, E.J.C.; Lau, Y.K. and Lim, C.H.
(1985):
Effects of hemodialysis and peritoneal dialysis on Antithrombin III and platelets. Nephron 40:25-28.
- * Woods, H.F.; Dawson, A.; Ash, G. and Weston, M.J. (1978):
Heparin-induced decrease in circulating antithrombin III.
Lancet 1, 209.
- * Yamakawa, M.; Yamamoto, T.; Kishimoto, T. et al., (1982):
Serum levels of acetate and TCA cycle intermediates during hemodialysis in relation to symptoms.
Nephron. 32:155.
- * Yawata, Y. and Jacob, H.S. (1975):
Abnormal red cell metabolism in patients with chronic uremia. nature of the defect and its persistence despite adequate hemodialysis.
Blood 45:231.
- * Ylikorkala, O.; Huttunen, K.; Jarvi, J. and Vlinikka, I. (1982):
Prostacyclin and thromboxane in chronic uremia effect of dialysis.
Clin. Nephrol. 18:83-7.
- * Yoshioko, K.; Miyata, H. and Uraoko, Y. (1981):
Plasma factor XIII level in children renal disease.
Nephron, 27:19-24.
- * Young, T.K. and Lee, S.C. (1978):
Gastrointestinal dialysis in the therapy of uremia.
Kidn. Int. 12:S-285.

*** Zingraff, J. (1979):**

**Chronic hemodialysis-vascular access. Nephrology, edited by
Hamburger J, Crosnier J, and Grunfeld J, John Wiley and sons
Inc. New York, London, Sidney, Toronto. 1211.**